Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now you know what new CEO has been doing since he came on board. His wife no doubt has been taking care of any other business, which no doubt "ain't" much.
4 divided by 2 = 2, right? $2/share
Yep, just like I said, and yes just part of the scheme.
Marv, he was just working the scheme. If you have been around especially clinical-stage type stocks, this is just common practice. That is why you trade them ONLY.
Should be getting selling for tax loss. $2 by years end.
Only because they have chose not to close it right now, but just wait and you will see there is nothing coming from this study.
Tells you a lot about management when they don't keep their Investors updated. Without retail TPIV would have to go belly up which they just might anyway being they have nothing coming close to market.
Sit back and relax, you in good hands. The scheme is working so you and I can buy in at $2 for a trade.
Don't you know if the "boss" has any news, he wouldn't be using his wife to promote TPIV, he would get it out like yesterday.
Dodger1, that is a liable statement you made. If true that is one thing but if false can bring on much trouble. For your sake I hope that is true, but I will wait for $2.
18 shares traded, can you dig it?
"Sorry just letting you know we got nothing that works in the immunotherapy field but others have so I plan to get into your pockets even more, hehe! Now take heart my wife will save us. Did I do good Mr Wilson, sir?"
This is my opinion. Wilson brings in the new guy with the objective of using him to sell the company. Wilson now after all these years sees there is no way he can raise enough money to prove TPIV's products. So the question is can TPIV sell for more than $32m. I don't think so. Half that maybe. Anyway I can see no gains coming from TPIV for retail.
Volume? Uh, do what?
They all say things like that, just part of the scheme.
Yes, he did, from CEO
If this was in the works, then why did Wilson step down? Makes no sense!
This appointment is all about raising money which might be good in the long term. Yet, tells me lower PPS is coming first.
Give credit when it is due. Marv called this one dead on!
BLCM just came off it's lifetime low last month. Only a few thousand in revenue, but 130m cash and 30m debt.
Well P1, what you got to say now?
How many years have past since then?
Wilson what about that $5 billion again? You want to update that one? Why not?
Hey Wilson, even a junkyard dog will bark sometimes.
Wasn't basing my statement on just todays activity - was looking at the chart.
Looks like years low about to be tested.
If Wilson had anything he would be buying the stock, period!
You talking about "top notch" Wilson? Naw, he Top Notch!
Yep, $2 is a given! 2017 just might pass with no milestones complete. But if one is complete that would move the stock PPS would be AstraZeneca's durvalumab. I suspect if there was any good coming from that something would have been reported, they have had plenty of time.
And how many shares has Wilson purchased with all that compensation? Hum?
But part of the scheme is just that, so the CEO can get rich, though the company might not ever make a buck.
I don't think a CEO should benefit from his company stock just by working the scheme. If stockholders(who provides funding) are not benefiting neither should the CEO.
As Chairman, CEO and President at TAPIMMUNE INC, Glynn Wilson made $626,400 in total compensation. Of this total $276,200 was received as a salary, $110,000 was received as a bonus, $0 was received in stock options, $191,000 was awarded as stock and $49,200 came from other types of compensation. This information is according to proxy statements filed for the 2016 fiscal year.
Glynn Wilson
Base Pay
$276,200
Bonus + Incentive Comp
$110,000
Total Cash Compensation
$386,200
Stock Award Value
$191,000 Option Award Value
$0 Total Equity
$191,000
Total Other
$49,200
Total Compensation
$626,400
Market cap should be cut at least a third. I come about this compairing TPIV with other stocks in same "wonder".
Mac, I knew years ago that a person have different opinions and I do not tried to stop one from expressing it. Actually I have become a better trader/investor by reading many post. Maybe one day you will move past what you believe about a poster into what you are able to know about a stock based on experience in dealing in a scheme, not hope for a come.
Yes, stocks are set up on a scheme. There is so much leadway given to CEO's by the system(the scheme). Also I have seen very few stocks that individual investors can have any power or control. You are at the mercy of those involved(the officers, their financial investors, the SEC, etc) in the scheme.
Now Mac, I suggest you worry about your own pocketbook and let all others worry about theirs.
Mac, most all stocks are a scheme, yet a good trader can make some good money in most all of them if he buys at the right price. But I don't have to answer your question, anyway I could lie to you just like you can lie to me.
Now with that being said it would be just fine with me if TPIV would become the grail for a cure of cancer(tpiv not even in trials now to cure cancer). But at this point and time and understanding the how the scheme works, I cannot see TPIV's market value this high.
To invest, I had rather buy in at say $10 a share on a proven solution to a problem than pay $.50/share based just on hope.
I am in the process of rethinking my position.
I think Marv might be right about the $.50 if results are bad as I believe they will be. This would be typical of of how the scheme works, in that shorts would jump on it. And this would be no problem for Wilson and company because they will just continue to dilute and R/S to maintain their listing and salaries.
Report on TPIV 200 in combination with AstraZeneca's durvalumab value will not be substantiated. All the other milestones put together will not add any actual value.
WOW, up 3 pennies, celebrate, celebrate dance to the music.
$2.50 next, $2, give me that horizon!